Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Depressive Disorders: MDD and Dysthymia

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Depression: Overview

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An Intervention to Support Higher Education Teachers' Teaching Processes and Well-Being: Protocol for an Intervention Study.

JMIR research protocols·2025

Same author

Automated diagnosis and classification of metacarpal and phalangeal fractures using a convolutional neural network: a retrospective data analysis study.

Acta orthopaedica·2025

Same author

From Thriving Developers to Stagnant Self-Doubters: An Identity-Centered Approach to Exploring the Relationship Between Digitalization and Professional Development.

Vocations and learning·2022

Same author

Improvement in indices of cellular protection after psychological treatment for social anxiety disorder.

Translational psychiatry·2019

Same author

Attentional Bias Modification in Virtual Reality - A VR-Based Dot-Probe Task With 2D and 3D Stimuli.

Frontiers in psychology·2019

Same author

Behavioral couples therapy versus cognitive behavioral therapy for problem gambling: a randomized controlled trial.

Addiction (Abingdon, England)·2019

Search research articles

Related Experiment Video

Updated: Apr 11, 2026

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Smartphone-Supported versus Full Behavioural Activation for Depression: A Randomised Controlled Trial.

Kien Hoa Ly¹, Naira Topooco¹, Hanna Cederlund¹

¹Department of Behavioural Sciences and Learning, Linköping University, Linköping, Sweden.

|May 27, 2015

Summary

This summary is machine-generated.

A new blended depression treatment combining face-to-face sessions and a smartphone app showed significant improvements but was not proven non-inferior to full behavioral activation. This approach may double patient capacity, offering a potentially cost-effective alternative.

More Related Videos

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

Related Experiment Videos

Last Updated: Apr 11, 2026

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

Area of Science:

Clinical Psychology
Digital Health
Mental Health Treatment

Background:

There is a critical need for more cost-effective and time-efficient depression treatments.
This study introduces a novel blended treatment approach for major depression, integrating face-to-face sessions with a smartphone application.
The trial registration number is NCT01819025.

Purpose of the Study:

To investigate if a blended treatment (four face-to-face sessions + smartphone app) is non-inferior to a full behavioral activation (BA) treatment for depression.
To assess the efficacy and potential cost-effectiveness of a smartphone-supported blended therapy model.

Main Methods:

A randomized controlled non-inferiority trial comparing a blended treatment (n=46) against a full ten-session behavioral activation treatment (n=47).
The primary outcome measure was the Beck Depression Inventory-II (BDI-II), assessed at pre-treatment, post-treatment, and six-month follow-up.
Therapist time was recorded to evaluate efficiency.

Main Results:

Both the blended and full BA treatment groups showed significant within-group improvements over time on the BDI-II.
No statistically significant difference was found between the groups for the primary outcome measure, failing to establish non-inferiority.
The blended treatment significantly reduced therapist time by an average of 47% compared to the full treatment.

Conclusions:

While non-inferiority was not established, the blended treatment demonstrated significant symptom reduction and reduced therapist time.
The smartphone-augmented approach has the potential to nearly double the number of depression patients treated, suggesting increased capacity.
Further research is necessary to confirm the blended treatment as a promising, cost-effective alternative to traditional face-to-face therapy for depression.